Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success
Salvatore Fiorenza, Cameron J. Turtle
BioDrugs (2021) Vol. 35, Iss. 3, pp. 281-302
Closed Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

CAR T-Cell Therapy in Hematological Malignancies
Theresa Haslauer, Richard Greil, Nadja Zaborsky, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8996-8996
Open Access | Times Cited: 131
Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities
Ilias Christodoulou, Won Jin Ho, Andrew Marple, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 12, pp. e003894-e003894
Open Access | Times Cited: 98
In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
Tianqing Xin, Cheng Li, Chuchao Zhou, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 59
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
Simona Caruso, Biagio De Angelis, Francesca Del Bufalo, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 58
A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021
Lele Miao, Juan Zhang, Zhengchao Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 56
Immunogenic cell death inducer peptides: A new approach for cancer therapy, current status and future perspectives
Hamid Aria, Marzieh Rezaei
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114503-114503
Open Access | Times Cited: 25
HA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation
Elizabeth F. Krakow, Michelle Brault, Corinne Summers, et al.
Blood (2024) Vol. 144, Iss. 10, pp. 1069-1082
Closed Access | Times Cited: 8
Recent advances of CAR-T cells in acute myeloid leukemia
Huan Deng, Qi Wang, Xiaodong Tong, et al.
Therapeutic Advances in Hematology (2025) Vol. 16
Open Access | Times Cited: 1
Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives
Salvatore Leotta, Annalisa Condorelli, Roberta Sciortino, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 1, pp. 253-253
Open Access | Times Cited: 34
Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis
Moazzam Shahzad, Andrea Nguyen, Ali Hussain, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 22
NPM1‐mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions
Brunangelo Falini
American Journal of Hematology (2023) Vol. 98, Iss. 9, pp. 1452-1464
Open Access | Times Cited: 20
Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells
Chiara F. Magnani, Renier Myburgh, Silvan Brunn, et al.
Molecular Therapy — Oncolytics (2023) Vol. 30, pp. 56-71
Open Access | Times Cited: 14
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia
Xuanqi Cao, Haiping Dai, Qingya Cui, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 19
Blood–brain barrier breakdown, central nervous system cell damage, and infiltrated T cells as major adverse effects in CAR-T-related deaths: a literature review
Fabio Del Duca, Gabriele Napoletano, Gianpietro Volonnino, et al.
Frontiers in Medicine (2024) Vol. 10
Open Access | Times Cited: 4
Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia
Xiangyu Wang, Yanming Zhang, Shengli Xue
Annals of Hematology (2024) Vol. 103, Iss. 6, pp. 1843-1857
Closed Access | Times Cited: 4
Identification of hub genes and immune-related pathways in acute myeloid leukemia: insights from bioinformatics and experimental validation
Mingliang Shan, Li Xu, Wenzhe Yang, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Current developments in T-cell receptor therapy for Acute Myeloid Leukaemia
Steven D. Gore, Emily Blyth, Marie Bleakley, et al.
Blood Advances (2025)
Open Access
Beyond TKIs: Advancing Therapeutic Frontiers with Immunotherapy, Targeted Agents, and Combination Strategies in Resistant Chronic Myeloid Leukemia
Imran Rashid Rangraze, Mohamed El‐Tanani, Adil Farooq Wali, et al.
Hemato (2025) Vol. 6, Iss. 1, pp. 6-6
Open Access
Visualization and hotspot analysis of CAR‐T research based on CiteSpace
Kejin Li, Yue Teng, Weiyan Tang, et al.
Precision Medical Sciences (2025)
Open Access
New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy
Fabio Andreozzi, Fulvio Massaro, Sébastian Wittnebel, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3887-3887
Open Access | Times Cited: 18
Challenges and optimal strategies of CAR T therapy for hematological malignancies
Weidong Han, Yang Xu, Xiuyong Dang, et al.
Chinese Medical Journal (2023)
Open Access | Times Cited: 9
Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game
Kimberly Ku, Jie Tang, Yuan Chen, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5361-5361
Open Access | Times Cited: 3
CAR-NK cell therapy in AML: Current treatment, challenges, and advantage
Mohammadmahdi Bahramloo, Sina Alinejad Shahabi, Hossein Kalarestaghi, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 117024-117024
Open Access | Times Cited: 3
Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy
Salvatore Fiorenza, Sheryl Y.T. Lim, George S. Laszlo, et al.
Deleted Journal (2024) Vol. 32, Iss. 3, pp. 200854-200854
Open Access | Times Cited: 3
Evolving strategies to overcome barriers in CAR-T cell therapy for acute myeloid leukemia
Chanukya K. Colonne, Erik L. Kimble, Cameron J. Turtle
Expert Review of Hematology (2024) Vol. 17, Iss. 11, pp. 797-818
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top